Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic
Titel:
Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic
Auteur:
Akimova, A. A. Banshchikova, N. E. Sizikov, A. E. Mullagaliev, A. A. Letyagina, E. A. Ilina, N. A. Kurochkina, Y. D. Ubshaeva, Y. B. Omelchenko, V. O. Chumasova, O. A. Shkaruba, N. S. Korolev, M. A.